Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early ...
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...
The appetites of biotech investors for companies expanding in artificial intelligence show no signs of slowing any time soon, as reflected by the stock surge enjoyed by Recursion Pharmaceuticals (RXRX ...
Recursion entered into a definitive agreement to combine with Exscientia to add its technology-enabled clinical pipeline, sector-leading partnerships, and precision chemistry capabilities Recursion ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, and I'm delighted to welcome you to our Earnings Call this morning. We're going to go ahead and get started. Perfect. So, of ...
Good morning and [Technical Difficulty] Healthcare Conference [Technical Difficulty] love to have you in Miami. [Technical Difficulty]. I'm Mani Foroohar, senior analyst, genetic medicines here at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results